PRGO (Perrigo Co) ROCE % : 2.19% (As of Mar. 2025)

View and export this data going back to 1991. Start your Free Trial

What is Perrigo Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Perrigo Co's annualized ROCE % for the quarter that ended in Mar. 2025 was 2.19%.

Perrigo Co ROCE % Historical Data

The historical data trend for Perrigo Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co ROCE % Chart

Perrigo Co Annual Data

Trend

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

1.33

4.05

0.18

1.73

1.20

Perrigo Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-2.43	-1.33	3.40	4.93	2.19

Perrigo Co ROCE % Calculation

Perrigo Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	107.1	/	( ( (10809.1 - 1586.3)	+	(9647.7 - 1044.2) )	/ 2 )
	=	107.1	/	( (9222.8	+	8603.5)	/ 2 )
	=	107.1	/	8913.15
	=	1.20 %

Perrigo Co's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	189.2	/	( ( (9647.7 - 1044.2)	+	(9759.8 - 1073.8) )	/ 2 )
	=	189.2	/	( ( 8603.5	+	8686 )	/ 2 )
	=	189.2	/	8644.75
	=	2.19 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Perrigo Co (NYSE:PRGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Perrigo Co ROCE % Related Terms

Thank you for viewing the detailed overview of Perrigo Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Perrigo Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0Y5E:UK PIG:Germany

Address

The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74

Website

https://www.perrigo.com

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Executives

Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Ronald Craig Janish	officer: EVP, Global Op. & Supply Chain	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Jeffrey B Kindler	director	35 E. 62ND ST, NEW YORK NY 10065
Katherine C. Doyle	director	100 ABBOTT PARK ROAD, AP6C-1N D032L, ABBOTT PARK IL 60064
Svend Andersen	director	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives	officer: EVP & Chief Scientific Officer	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Robert Willis	officer: Acting CHRO	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Patrick Lockwood-taylor	director, officer: CEO	C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Eduardo Guarita Bezerra	officer: EVP & Chief Financial Officer	C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Julia M Brown	director	C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter	officer: EVP & President CSCA	2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Murray S Kessler	director, officer: CEO	714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington	officer: Senior VP and CIO	4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii	officer: EVP, Chief Scientific Officer	6601 WEST BROAD STREET, RICHMOND VA 23230
Grainne Quinn	officer: EVP, Chief Medical Officer	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010